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The importance of cardiac fibroblasts in the regulation of myocardial remodelling following myocardial infarction
(MI) is becoming increasingly recognised. Studies over the last few decades have reinforced the concept that
cardiac fibroblasts are much more than simple homeostatic regulators of extracellular matrix turnover, but are
integrally involved in all aspects of the repair and remodelling of the heart that occurs following MI. The plasticity
of fibroblasts is due in part to their ability to undergo differentiation into myofibroblasts. Myofibroblasts are
specialised cells that possess a more contractile and synthetic phenotype than fibroblasts, enabling them to
effectively repair and remodel the cardiac interstitium to manage the local devastation caused by MI. However, in
addition to their key role in cardiac restoration and healing, persistence of myofibroblast activation can drive
pathological fibrosis, resulting in arrhythmias, myocardial stiffness and progression to heart failure. The aim of this
review is to give an appreciation of both the beneficial and detrimental roles of the myofibroblast in the
remodelling heart, to describe some of the major regulatory mechanisms controlling myofibroblast differentiation
including recent advances in the microRNA field, and to consider how this cell type could be exploited
therapeutically.
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Introduction
At the cellular level, heart tissue constitutes
cardiomyocytes, cardiac fibroblasts, vascular and
neuronal cells, as well as inflammatory cells under
certain pathological conditions. In the healthy heart,
cardiac fibroblasts are the most prevalent cell type,
accounting for up to 70% of cells, depending on the
species in question [1,2]. Although cardiac fibroblasts
have been much less well studied than cardiomyocytes,
it is becoming increasingly apparent that the fibroblasts
(and their differentiated phenotype, myofibroblasts)
are integral to the development, normal function and
repair of the heart, as well as contributing to adverse
myocardial remodelling, fibrosis and heart failure pro-
gression [3,4]. Through physical and biochemical* Correspondence: n.a.turner@leeds.ac.uk
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distribution, and reproduction in any mediumcommunication with myocytes and other cell types in
the heart and the cardiac extracellular matrix (ECM),
fibroblasts are well placed to sense and respond to
stress or injury to the myocardium.
Fibroblasts are a heterogeneous population of cells,
reflecting both their multiple developmental origins and
their exposure to differential physical and chemical
microenvironments. Fibroblasts derived from different
anatomical sites have been proposed to effectively repre-
sent distinct differentiated cell types as they exhibit
unique transcriptional signatures that probably reflect
phenotypic differences [5]. Such diversity has made
precise characterisation of fibroblasts challenging, and
there remains no truly unique single marker that un-
equivocally identifies a cell as a fibroblast [6].
Although fibroblasts have the capacity to proliferate,
migrate and regulate ECM turnover to maintain cardiac
homeostasis, they are also able to undergo differenti-
ation into a more contractile and synthetic myofibroblast
phenotype to aid with cardiac repair following myocar-
dial infarction (MI) [7-9]. Myofibroblasts are not nor-
mally found in the healthy myocardium, but are thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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main effectors of fibrogenesis [10]. Myofibroblasts are
characterised by increased expression of particular con-
tractile proteins (for example, α-smooth muscle actin,
SMemb, vimentin), focal adhesion proteins (for example,
paxillin, tensin, αVβ3 integrin), cell surface receptors
(for example, transforming growth factor beta (TGF-β)
type II receptor, angiotensin AT1 receptor, Frizzled-2),
structural ECM proteins (collagen I, collagen III,
fibronectin extra domain A splice variant (FN-ED-A))
and matricellular proteins (for example, periostin,
osteopontin, tenascin C) [7-9]. Cardiac myofibroblasts
are also highly proliferative, and those isolated from
infarcted myocardium exhibit a higher rate of
proliferation than cardiac fibroblasts from remote areas
[11,12]. Although myofibroblasts are able to actively mi-
grate to the infarcted region of the heart [13], a process
regulated by Wnt/Frizzled signalling [14,15], they also
appear to become less migratory as expression levels of
contractile proteins increase [11,16]. Together these
phenotypic changes confer increased tensile and ECM-
secretory characteristics on the cells, enabling them to
effectively facilitate the wound healing process.
Beneficial and detrimental roles of myofibroblasts
Appreciating the dual roles of cardiac myofibroblasts in
the myocardial remodelling process is important, as they
can be perceived to be both beneficial and detrimental
depending on their prevalence and their temporal and
spatial location. The infarct scar is not a simple acellularS
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arrhythmia and heart failure progression.structure comprising structural ECM molecules; on the
contrary, it contains myofibroblasts that maintain a vi-
able, dynamic scar important for maintaining myocardial
integrity against a background of continuous mechanical
forces associated with the pumping of the heart [17].
Myofibroblasts are essential for rapid and robust (that is,
strong and flexible) scar formation following MI. Inter-
ference with myofibroblast recruitment can result in in-
farct expansion, ventricular wall thinning, dilatation,
systolic dysfunction and propensity to rupture [7]
(Figure 1). Conversely, myofibroblast persistence can
contribute to fibrosis and adverse myocardial remodel-
ling, particularly if the myofibroblasts remain active in
otherwise healthy areas of the heart away from the ori-
ginal site of injury (reactive fibrosis) [7]. Areas of
increased ECM protein deposition can disturb the elec-
trical conductance of the myocardium, thus increasing
the likelihood of arrhythmias [18]. Moreover, direct
coupling of cardiomyocytes to myofibroblasts, as
opposed to fibroblasts, may also promote arrhythmias
[19,20]. Fibrosis in the remote myocardium inevitably
leads to increased myocardial stiffness, resulting in sys-
tolic and diastolic dysfunction, neurohormonal activa-
tion and, ultimately, heart failure [21,22] (Figure 1).
Origin of myofibroblasts
The differential origin of myofibroblasts in the remodel-
ling heart has become a hot topic in recent years [6,23].
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tude of alternative cellular precursors. These precursors
include epithelial cells (through a process termed epithe-
lial–mesenchymal transition), endothelial cells (through
endothelial–mesenchymal transition; EndMT), mesen-
chymal stem cells, bone marrow-derived circulating pro-
genitor cells (fibrocytes), smooth muscle cells and
pericytes [6,23]. The recruitment of myofibroblasts from
such diverse origins underlines their importance in the
cardiac repair process, and probably represents
optimised responses to different types of stress or injury.
However, reports on the precise proportions of cells
derived from different sources in different experimental
models have varied considerably, so consensus has yet to
be reached on the relative importance of myofibroblasts
derived from resident cardiac fibroblasts versus extra-
cardiac sources [6]. Another important aspect is whether
these data are recapitulated in the human scenario.
Nevertheless, a picture is now emerging that the source
of myofibroblasts in the remodelling heart may depend
heavily upon the nature of the initiating stimulus or in-
jury. For example, whereas resident mesenchymal stem
cells have been identified as important contributors to
the myofibroblast population that drives post-MI scar
formation, fibrocyte-derived myofibroblasts may be more
important for interstitial fibrosis in the absence of MI
[24]. Such knowledge opens up the exciting prospect that
selective targeting of distinct myofibroblast populations
could be used to protect essential repair mechanisms
following MI, whilst reducing remote fibrosis and subse-
quent adverse myocardial remodelling.
Factors stimulating myofibroblast differentiation
Phenotypic conversion of resident cardiac fibroblasts to
myofibroblasts requires integration of both mechanical and
biochemical stimuli. Fibroblasts are mechanosensitive and
are therefore able to detect the loss of integrity of the ECM
that occurs following MI. In response to increased mechan-
ical stress and platelet-derived growth factor, fibroblasts
adopt a partially differentiated phenotype known as
the proto-myofibroblast [8]. Conversion of the proto-
myofibroblast to the fully differentiated myofibroblast
occurs in response to additional biochemical signals, par-
ticularly increased levels of active TGF-β and FN-ED-A [8],
the levels of which are elevated in the damaged region of
the heart post MI [25,26]. Such a phenotypic conversion is
also promoted when cardiac fibroblasts are grown in vitro
on rigid plastic surfaces; hence studies on cultured cardiac
fibroblasts are generally indicative of myofibroblast behav-
iour [16,27]. TGF-β is normally present in the interstitium
in a latent form, which can be rapidly activated by
protease-mediated cleavage of the latency-associated pep-
tide [28]. However, it has also been demonstrated that
TGF-β activation can be stimulated directly by mechanicalstrain without the need for protease activity [29], and this
mechanosensitive mechanism probably plays an important
role in early myofibroblast conversion.
A number of additional stimuli that promote differen-
tiation to the myofibroblast phenotype have been
reported, including specific cytokines, growth factors
and ECM molecules; several of which elicit their effects
through up regulation of TGF-β activity and/or signal-
ling [30]. There is also emerging evidence for an import-
ant role for the transient receptor potential family of ion
channels in regulating cardiac myofibroblast differenti-
ation. For example, the TRPM7 channel [31], the
mechanosensitive TRPV4 channel [32] and the TRPC6
channel [33] have all recently been shown to be import-
ant for differentiation of cardiac fibroblasts in vitro. The
latter study also employed an experimental MI model
with TRPC6 knockout mice to show that myofibroblast
differentiation was attenuated in vivo and this
manifested in reduced infarct size, increased ventricular
dilatation, reduced cardiac function and increased mor-
tality due to ventricular wall rupture [33].
TGF-β-induced myofibroblast differentiation can be
opposed by proinflammatory cytokines (for example,
TNFα, IL-1) that may contribute to the temporal and
spatial regulation of myofibroblast function in the transi-
tion from inflammatory to granulation and maturation
phases of infarct healing [34]. Basic fibroblast growth
factor can also inhibit TGF-β-induced myofibroblast dif-
ferentiation, and was recently identified as an important
paracrine factor that led to improved cardiac function
following cell therapy in a rat MI model [35].
Factors regulating myofibroblast persistence
Although myofibroblasts play key roles in scar forma-
tion, in most tissues (for example, skin) they usually
undergo apoptotic cell death once the scar has matured
and the healing process is resolved [36]. In the heart,
however, whilst the density of scar myofibroblasts
decreases rapidly in the weeks following MI [37-40], sig-
nificant numbers can persist for many years [41]. A
major driver of myofibroblast apoptosis in the heart and
other tissues is thought to be a release from mechanical
stress [42]. Repair of the damaged tissue with an
organised cross-linked collagen-based ECM shields the
myofibroblasts from mechanical stress, triggering the
cells to proceed down an apoptotic pathway [42]. Add-
itionally, cardiac myofibroblasts express the Fas receptor,
and Fas activation is important in scar myofibroblast
apoptosis after MI [43]. Strategies aimed at reducing
myofibroblast apoptosis have reported favourable effects
on infarct scar healing. For example, inhibition of Fas/
Fas ligand interaction in mice 3 days after MI reduced
apoptosis of myofibroblasts and macrophages, resulting
in a thick, contractile and highly cellularised scar and
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sion and death [43].
Recent in vitro evidence obtained using porcine aortic
valve myofibroblasts suggests that fully differentiated
myofibroblasts may also have the capacity to revert back
to quiescent fibroblasts when substrate rigidity is
reduced [44]. Furthermore, manipulation of TGF-β
-induced signalling molecules (for example, c-Ski) may
also promote reversal of the myofibroblast phenotype
[45]. These studies highlight the potential plasticity of
the myofibroblast phenotype that could make it amen-
able to therapeutic exploitation in the heart.
Importantly, while reducing apoptosis of myofibroblasts
in the scar may deliver short-term beneficial effects, per-
sistence of myofibroblasts in remote regions of the heart
away from the scar area is detrimental. This is particularly
relevant to nonischaemic cardiac remodelling such as left
ventricular hypertrophy associated with pressure overload,
in which myofibroblast persistence drives a profibroticEndothelial cell
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Epigenetics and microRNAs
Recent advances in a number of laboratories have revealed
a role for epigenetics in influencing the differentiation
process of myofibroblasts and resultant fibrogenesis
(reviewed in [9]). These epigenetic influences include DNA
methylation, post-translational histone modifications and
regulatory noncoding RNAs, all of which can have pro-
found effects on gene expression that control cell pheno-
type and function [48]. MicroRNAs (miRs) are the most
widely investigated noncoding RNAs, acting as negative
regulators of gene expression by inhibiting mRNA transla-
tion or promoting mRNA degradation [49]. There has
been considerable interest in miR regulation of the
myofibroblast phenotype in a variety of organs (reviewed
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cardiac remodelling, and amongst those commonly reported
are miR-133 (the most abundant in human heart), miR-1,
miR-21, miR-29 and miR-208 (reviewed recently in [51]).
Whilst early studies initially focused on the cardiomyocyte
population, interesting roles for miRs specifically associated
with cardiac fibroblasts and/or myofibroblasts are now
emerging (Figure 2).
Differentiated myofibroblasts play central roles in
fibrogenesis through their ability to synthesise increased
quantities of ECM proteins. However, recent new data
suggest that differential expression of miRs, and specific-
ally elevated levels of miR-125b, can regulate the process
of cardiac EndMT to a fibroblast-like phenotype in mur-
ine cells and promote profibrotic signalling [52]. Another
study concluded that miR-21 contributes, at least in part,
to EndMT in human umbilical vein endothelial cells [53].
Taken together these data support the idea that specific
anti-miR targeting holds potential to ameliorate fibrosis
by restricting the generation of myofibroblasts specifically
derived through EndMT.
Differentiation of fibroblasts in the stressed myocardium
confers ability to upregulate ECM turnover towards
augmented fibrosis. A number of miRs have emerged as
important regulators in this mechanism, and miR-21 and
miR-29 have proven to be of particular interest. Whilst
miR-21 expression is prominent in cardiac fibroblasts and
substantially weaker in myocytes, increased miR-21 expres-
sion observed in failing murine hearts has been shown to
be of fibroblast origin [54]. In that study, miR-21 targeting
of Sprouty homologue, a negative regulator of the
mitogen-activated protein kinase signalling pathway, led to
increased fibroblast growth factor secretion, fibroblast sur-
vival and increased fibrosis [54]. In a different study, miR-
21-mediated matrix metalloproteinase-2 expression in
murine fibroblasts was reportedly via direct targeting of
the phosphatase and tensin homologue, a negative regula-
tor of the phosphatidylinositol 30-kinase–AKT signalling
pathway [55]. Whilst increased matrix metalloproteinase-2
secretion would imply increased degradation of ECM and
fibroblast migratory activity, these processes were not dir-
ectly investigated.
In the heart, miR-29 is mainly expressed in fibroblasts
and has been shown to be downregulated in viable
myocardium after experimental MI [56]. In the same
study, the authors demonstrated that TGF-β stimulation
of cultured cardiac fibroblasts downregulated miR-29 ex-
pression, suggesting that TGF-β drives the decrease in
miR-29 in the remodelling heart. The first demonstra-
tion that miR-29 directly targets multiple ECM genes led
to the proposal that miR-29 represses ECM gene expres-
sion in healthy myocardial fibroblasts and that miR-29
loss probably contributes to cardiac fibrosis by relieving
this repression [56]. miR-29 has also been associatedwith apoptosis through modulating p53 activity [57], al-
though this was demonstrated in a fibroblast cell line
and would require validation in cardiac fibroblasts.
Taken together these studies suggest that miR-29
therapeutics may be beneficial in regressing cardiac
fibrosis.
An observed correlation between miR-24 expression and
fibrosis in hypertrophic hearts was pursued in a recent
study in which miR-24 was shown to be downregulated
after MI and related to ECM remodelling [58]. Myocardial
injection of miR-24 improved heart function and
attenuated fibrosis and, notably, overexpression of miR-24
in cultured cardiac fibroblasts was also able to decrease dif-
ferentiation to myofibroblasts through a reduction in TGF-
β secretion and Smad phosphorylation [58].
In the healthy heart, it appears that expression of miR-
133a and miR-30 are able to control ECM turnover by
maintaining low secreted levels of the profibrotic
cytokines TGF-β and connective tissue growth factor
(CTGF/CCN2); a number of reports have demonstrated
that miR-133a and miR-30 are downregulated in rodent
and human heart failure [59,60]. miR-133a, whilst
expressed only in myocytes and not fibroblasts, is
believed to influence fibrosis through a paracrine mech-
anism that controls CTGF and TGF-β [60]. miR-30 is
highly expressed in cardiac fibroblasts, however, and is
believed to act in a manner similar to that of miR-29 –
namely, by de-repression of profibrotic genes [60] – al-
though whether fibrosis can be manipulated in vivo by
miR-30 requires verification in functional studies.
Therapeutic regulation
The challenge of post-MI therapeutic regulation at the
level of the cardiac myofibroblast is to encourage
optimum myofibroblast recruitment and retention in the
scar (reparative fibrosis), whilst reducing myofibroblast ac-
tivity in remote non-infarcted areas of the myocardium
(reactive fibrosis). Several commonly prescribed drugs for
MI patients that deliver beneficial effects on adverse car-
diac remodelling appear to do so in part by directly influ-
encing cardiac fibroblast and myofibroblast behaviour.
Such drug classes include angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, β-blockers,
statins and thiazolidinediones (reviewed in [3,47,61]).
However, regulation of cardiac (myo)fibroblast activity is
not the primary target of these pharmacological agents,
but instead appears to be an added pleiotropic benefit.
What about strategies designed specifically to target
fibrogenesis? In light of our current knowledge of the
mechanisms involved in post-MI repair and remodelling,
some important considerations include: precisely con-
trolling temporal administration of antifibrotic therapies
to optimise scar formation, but ameliorate subsequent
reactive fibrosis; targeting individual molecules that play
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and selective targeting of myofibroblast populations
derived from different sources that play diverse roles in
post-MI remodelling. Some such strategies are discussed
briefly hereafter.
Transforming growth factor beta pathway
TGF-β is one of the most important inducers of the
myofibroblast phenotype, as well as being an important
profibrotic signalling molecule in its own right [28].
Inhibition of TGF-β activity before MI reduces the ef-
fectiveness of scar formation, leading to increased ven-
tricular dilatation, decreased cardiac function and higher
mortality rates, whereas TGF-β inhibition at later times
after MI reduces adverse reactive fibrosis [62,63].
Because of the ubiquitous role of TGF-β in regulating tissue
fibrosis, more selective strategies have attempted to target
specific components of the TGF-β signalling pathway. For
example, knockout of Smad3 increased myofibroblast dens-
ity in the infarct scar in mice, whilst reducing interstitial
myofibroblast numbers, decreasing dilatation and improv-
ing cardiac function compared with wild-type animals [64].
Other regulators of TGF-β signalling that have been
proposed as therapeutic targets include the proto-oncogene
c-Ski, the basic helix–loop–helix transcription factor
Scleraxis and the proteasome E3 ligase Arkadia [65,66].
Matricellular proteins
The ability of TGF-β to induce fibroblast differentiation
and fibrogenesis can also be regulated by matricellular
proteins; a group of ECM-associated regulatory proteins
that are expressed only under pathological conditions in
the heart [42]. Ongoing studies suggest that some of these
proteins may be viable therapeutic targets for regulating
TGF-β activity and its downstream consequences, includ-
ing myofibroblast accumulation and activation [42].
For example, tenascin C appears to be important for
myofibroblast recruitment (differentiation and migration)
to injured areas of the heart [67], but also contributes to
adverse ventricular remodelling, fibrosis and heart failure
after MI [68]. Periostin is important for infarct healing by
promoting myofibroblast recruitment and collagen synthe-
sis [69,70]. Periostin knockout mice subjected to experi-
mental MI had increased rates of cardiac rupture, although
those that survived had less fibrosis and improved cardiac
function [69,70]. Thrombospondin-1 may help to limit the
inflammatory phase of infarct healing and prevent the
damaged area spreading to non-infarcted tissue [71], as
well as being necessary for myofibroblast maturation and
fibrogenesis in the pressure-overloaded heart [72]. CTGF
(CCN2) is a multi-functional matricellular protein whose
levels are elevated in both myocytes and myofibroblasts in
the infarcted zone after experimental MI [73]. CTGF
enhances TGF-β-induced fibroblast differentiation tomyofibroblasts and appears to play an important role in
neovascularisation [74]. CTGF probably plays a critical
role in post-MI fibrosis, but such assumptions are based
largely on observational data and therefore further studies
with CTGF inhibition/knockdown are required to more
precisely define its importance in regulating myofibroblast
function in this context [74]. Osteonectin (SPARC) is an-
other matricellular protein that is important for infarct
healing, as mice deficient in SPARC exhibited adverse
healing and deficient collagen maturation after MI, leading
to increased cardiac rupture and dysfunction [75]. In a
separate mouse study, SPARC deletion improved cardiac
function 3 days after MI, but the absence of SPARC also
resulted in impaired fibroblast activation and attenuated
the increase in ECM production [76].
Wnt/Frizzled pathway
The Wnt/Frizzled signalling pathway has been shown to
be an important modulator of the migration and differ-
entiation of cardiac fibroblasts in vitro [14]. Moreover, in
a mouse model of MI, administration of a specific pep-
tide antagonist of Frizzled increased myofibroblast
numbers and revascularisation in the infarct area,
prevented infarct expansion, improved cardiac function
and prevented heart failure mortality [15]. The potential
therapeutic value of the Wnt/Frizzled signalling axis has
been extensively reviewed recently [77].
Fibronectin extra domain A splice variant
FN-ED-A is an important contributor to the innate in-
flammatory response, as well as being a major driver
of myofibroblast differentiation [8,78]. FN-ED-A is
upregulated in the infarct area and remote myocardium
following MI [25]. In an MI model using FN-ED-A
knockout mice, infarct collagen levels (reparative fibro-
sis) were comparable with those of wild-type mice; how-
ever, reactive fibrosis in the remote non-infarcted area
was reduced compared with wild-type animals, and con-
ferred improvements in systolic and diastolic function
and mortality [25]. Targeting FN-ED-A may therefore be
an attractive therapy that is selective for reactive, rather
than reparative fibrosis.
Myocardin-related transcription factor A
Myocardin-related transcription factor A (MRTF-A)
appears to be a key inducer of gene programmes that
mediate both cardiomyocyte hypertrophy [79] and fibro-
blast differentiation and fibrosis [80]. MRTF-A knockout
mice exhibited a marked reduction in MI scar size with
less myofibroblasts, but no detrimental effect on cardiac
rupture or mortality [80]. Angiotensin II-induced react-
ive fibrosis was reduced in MRTF-A deficient mice
compared with wild-type littermates [80]. MRTF-A may
thus represent another potential therapeutic target for
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ising infarct scar healing.
Targeting different myofibroblast subsets
As discussed earlier, myofibroblasts in the remodelling
heart are derived not only from resident cardiac
fibroblasts, but also from endothelial cells (via EndMT),
epithelial cells, mesenchymal stem cells, bone marrow-
derived fibrocytes, smooth muscle cells and pericytes
[6,23]. Therapeutic manipulation of the mechanisms
involved in recruiting myofibroblasts from these different
sources may therefore hold potential for modulating car-
diac remodelling under different pathological conditions.
For example, monocyte chemotactic protein 1 (MCP-
1/CCL2) is important for fibrocyte recruitment [81].
Cardiac overexpression of MCP-1 improves post-MI car-
diac function and remodelling, at least in part by in-
creasing myofibroblast accumulation [82]. Furthermore,
MCP-1 deletion in a murine angiotensin II infusion
model of interstitial fibrosis was demonstrated to reduce
the number of CD34+/CD45+ (that is, fibrocyte-derived)
myofibroblasts with resultant loss of interstitial fibrosis
[83]. Rho kinase (ROCK-1) has also been identified as an
important molecule regulating MCP-1-induced differen-
tiation of CD34+/CD45+ fibrocytes into myofibroblasts
in an ischaemic cardiomyopathy model [84]. Hearts
from ROCK-1 null mice exhibited reduced numbers of
fibrocytes and myofibroblasts, accompanied by reduced
fibrosis and reduced cardiac dysfunction compared with
wild-type animals [84]. One should note, however, that
chemokines such as MCP-1 have far-reaching activities
that are fundamental to the post-MI inflammatory
process (for example, macrophage recruitment and ac-
tivity) [85], and thus their targeting affects processes that
extend beyond simple modulation of myofibroblast der-
ivation from fibrocytes. Also, as with all animal studies,
an element of caution should be exercised when
considering knockout mouse results in relation to the
situation in humans. For example, marked differences in
MCP-1 expression levels post MI have been noted be-
tween mice and humans [86].
Nevertheless, as our knowledge on the origins of
myofibroblasts in the heart increases, this will hopefully
reveal novel therapeutic targets in addition to those
described above. For example, it would be interesting to
determine the effects of modulating miR-125b, as this
has been shown to be important for regulating EndMT
in the heart [52]. Strategies to target miRs will be
discussed in more detail below.
MicroRNAs
The development and/or progression of many human
pathologies is now widely accepted to be attributed
to dysregulation of miRs, and understanding theirfunctional relevance will advance exploitation of these
molecules as therapeutic targets. Moreover, the tightly
regulated cell type specificity of miR expression makes
these molecules amenable to modulating function of in-
dividual cell types. Whilst current pharmacological ther-
apies used in the treatment of adverse cardiac
remodelling and failure are known to retard its progres-
sion, mortality rates remain high and there is a clear
need for new therapies [87]. Whilst traditional therapies
normally focus on a single target (for example, AT1R, β-
AR) [3], by their very nature miRs regulate multiple
genes, often within similar molecular pathways and sig-
nalling cascades. As such, they have potential to influ-
ence complex networks that are activated by a single
stimulus (reviewed in [88]). For example, the miR-29
family is remarkably influential in regulating mRNA ex-
pression of a variety of collagens [56]. On the contrary,
the breadth of miR-mediated effects also brings potential
for disrupting cellular function through unwanted side
effects [89].
Molecular tools for manipulating miR levels (through
inhibition or mimicry) have been an area of rapid devel-
opment and ongoing refinement [88]. As discussed
above, several promising miR targets have been identi-
fied that appear to regulate myofibroblast differentiation
and/or function (Figure 2). Preclinical studies manipulat-
ing miR-21 and miR-29 have shown beneficial effects on
post-MI cardiac remodelling in rodents. Specifically, a
miR-29 mimetic has proven successful in a murine
model of cardiac fibrosis [56] and miR-21 inhibition
increased survival after MI [55].
Progressive expansion of our knowledge concerning
dysregulation of miRs in cardiac (myo)fibroblast pheno-
type and function will undoubtedly lead to strategies
that optimise targeted delivery of miR therapeutics. The
ability to deliver therapies directly to selected cell types
is indeed a realistic option for future medicine.
Conclusions
Cardiac myofibroblasts represent a unique, yet develop-
mentally diverse, population of cells that play key roles
in post-MI infarct healing, but also in adverse cardiac re-
modelling, fibrosis and progression to heart failure.
Improved understanding of not only the origins of
myofibroblasts in the post-MI heart, but also the cap-
acity to assign specific roles and regulatory mechanisms
to them, creates optimism for the future that this multi-
functional cell type can be manipulated therapeutically
to optimise infarct scar formation, whilst ameliorating
reactive fibrosis.
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